Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19 |
| |
Authors: | L. Tom Vlasveld Annemarie Hekman Florry A. Vyth-Dreese Cornelis J. M. Melief Johan J. Sein Arie C. Voordouw Trees A. M. Dellemijn Elaine M. Rankin |
| |
Affiliation: | (1) Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands;(2) Division of Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Huis, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands;(3) Present address: Diaconessenhuis, Eindhoven, The Netherlands;(4) Present address: Department of Immunohaematology and Blood Bank, Academic Hospital, Leiden, The Netherlands |
| |
Abstract: | Seven patients with low-grade non-Hodgkin's lymphoma were treated with a combination of a murine monoclonal antibody directed against the B-cell-specific antigen CD19 (CLB-CD10), given twice weekly, and continuous infusion of low-dose recombinant interleukin-2 (rIL-2). We demonstrated stable serum CLB-CD19 levels throughout the 12 weeks of treatment, and homing of the antibody into the tumour sites. A variable degree of antigenic modulation was noted. Prolonged treatment resulted in a sustained increase in the number of natural killer cells in the circulation with enhanced cytotoxic capacity, including antibody-dependent cellular cytotoxicity. During the first weeks of treatment, T cell activation occurred in the majority of patients. Toxicity was related to the rIL-2 treatment and consisted of transient constitutional symptoms and a flu-like syndrome without organ dysfunction. A partial remission occurred in one patient, and in another patient who was primarily leukaemic a greater than 50% reduction of circulating B cells was noted. An antitumour effect occurred early during treatment and could not be related to rIL-2-induced modulation of natural killer cell or T lymphocyte activation. |
| |
Keywords: | Interleukin-2 Anti-CD19 antibody Monoclonal therapy |
本文献已被 SpringerLink 等数据库收录! |
|